DURHAM, N.C.--(BUSINESS WIRE)--Argos Therapeutics today announced the issuance of United States Patent 7,169,898, which covers soluble forms of the protein CD83. Soluble forms of CD83 can be used to treat a variety of disease indications resulting from unabated cellular immune responses, including autoimmune disorders such as multiple sclerosis, as well as for transplantation rejection.
